Saturday

30th Apr 2016

EU fines pharma-giants €427mn in ‘pay for delay’ case

  • French pharma-giant Servier was among a string of firms fined over €400 million in the EU's largest 'pay for delay' case. (Photo: Grumpy-Puddin)

French pharmaceutical firm Servier will bear the brunt of a €427 million anti-trust fine in the largest ‘pay for delay’ case brought by the European Commission.

Speaking at a news conference on Wednesday (9 July), EU competition commissioner Joaquin Almunia said Servier was guilty of protecting its bestselling blood pressure drug, perindopril, from price competition by generics in the EU between 2005 and 2007.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

Perindopril generated more than $1 billion per year in sales for Servier, revenues which the company feared it would lose when its patent control over the drug’s molecule expired. Servier then bought the technology needed to develop an alternative version and made a series of patent settlements with companies trying to produce generic forms of the drug.

Servier now faces a €330 million fine, while Niche/Unichem, Matrix Teva, Krka and Lupin - all producers of generic medicines - face fines totalling €97 million.

Internal documents of one generic company acknowledged that it was being "bought out of perindopril," while another insisted that any settlement with Servier would have to be for a "pile of cash".

Describing the behaviour as a “serious breach” of the bloc’s competition rules, Almunia added that “’pay for delay’ is clearly not acceptable”.

For its part, Servier’s spokesperson Lucy Vincent described the ruling as “a bad sign” and indicated that the company plans to appeal. Servier had “acted in a transparent and legitimate way to defend its patents,” she said.

The case is the largest "pay for delay" case brought by the EU executive, where a company has paid off rival firms to prevent them producing cheaper generic versions of a drug.

Pharmaceutical firms use a variety of means including secondary patents and ‘pay for delay’ settlements to prevent rivals from producing generic version of their drugs at a fraction of the price.

But anti-trust regulators in the US and the EU are now investigating a series of similar cases.

Last November, the Commission fined Johnson & Johnson, Novartis, and Lundbeck for paying off their rivals in the EU’s first ‘pay for delay’ cases.

“A company tried hard to unduly prolong its exclusively … not thanks to its innovation and the strength of its patents but thanks to its deep pockets and the complicity of its rivals,” commented Almunia.

“Pharmaceuticals companies should focus their efforts on innovating rather than trying to extract extra rents for patients and taxpayers,” he added.

News in Brief

  1. Netherlands funds €1.3mn Russian media project
  2. Fake euros network dismantled in Bulgaria
  3. Inflation negative in eurozone in April
  4. EU economy registers 0.5% growth in first quarter
  5. Eurovision says No to Kosovo, Palestine, IS flags
  6. EU to decide on future of tobacco agreement 'soon'
  7. Russia blames Sweden for frosty relations
  8. UN chief warns of 'growing xenophobia' in Europe

Stakeholders' Highlights

  1. European Roundtable of IndustrialistsDigitising European Industry
  2. Counter BalanceParliament Gets Tough on Control EU Bank's Funds
  3. ICRCSyria: Aleppo on the Brink of Humanitarian Disaster
  4. CESIWorld Day For Health and Safety at Work: Public Sector Workers in The Focus
  5. EFABasque Peace Process-Arnaldo Otegi Visits the European Parliament
  6. EscardioChina Pays Price of Western Lifestyle With Soaring Childhood Obesity
  7. Centre Maurits CoppetiersThe Existence of a State is a Question of Fact, Not a Question of Law
  8. Martens CentreJoin Us at The Event: Prospects For EU Enlargement After 2019
  9. ICRCSyria: Aid for Over 120,000 People Arrives in Besieged Town Near Homs
  10. Counter BalanceHighway to Hell: European Money Fuelling Controversial Infrastructure Projects
  11. EPSUResponds To Reported €300 Million McDonald’s Tax Bill in France
  12. Access NowAcademics and Privacy Groups Ask Obama to Reject Anti-encryption Law

Latest News

  1. EU fiscal rules, migrants and Belgium's trick
  2. EU should call out Bangladesh on workers' rights
  3. Kosovo: Living in a ghetto on the EU fringe
  4. War crimes law poisons Serbia accession talks
  5. Italy and Austria try to calm tensions on Alpine pass
  6. French MPs call to lift Russia sanctions
  7. EU sides with embattled Greek PM in bailout talks
  8. Former EU commissioners to testify in emissions probe